Cash Flow Statement (Annual)

HCOM / Hawaiian Telcom Holdco, Inc. Cash Flow Statement shows changes in cash positions over time. Cash Flow Statement data includes Cash from Operating Activities (CFOP), Cash from Investing Activities, and Cash from Financing Activities.

All numbers are times 1,000 except per share units.

2011 2012 2013 2014 2015 2016 2017
Net Cash Provided By Used In Operating Activities
  Profit Loss - - - - 1,100 1,106 -107,241
  Net Cash Provided By Used In Operating Activities - - - - 90,596 90,088 98,710
Net Cash Provided By Used In Operating Activities Continuing Operations
  Net Income Loss Available To Common Stockholders Basic 26,155 109,982 10,488 8,099 1,100 1,106 -107,241
  Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
    Depreciation Depletion And Amortization 63,806 70,908 77,301 78,014 87,879 89,916 88,424
    Amortization Of Financing Costs - - 1,813 1,855 1,922 2,068 1,442
    Gains Losses On Extinguishment Of Debt - -5,112 -3,660 - - - -4,826
    Gain Loss On Disposition Of Assets1 - - 6,546 - - - -
    Pension And Other Postretirement Benefit Expense Net Of Contributions Paid -9,920 -11,933 -13,224 -12,078 -3,634 -8,103 -1,720
    Pension And Other Postretirement Benefits Expense Reversal Of Expense Noncash - - - - - - -
    Provision For Doubtful Accounts 2,940 716 3,455 3,590 3,648 4,031 3,797
    Share Based Compensation 2,135 1,872 2,736 4,174 1,584 2,303 2,827
    Deferred Income Tax Expense Benefit - -90,827 9,617 6,851 1,958 1,332 88,628
    Increase Decrease In Operating Capital
      Increase Decrease In Receivables 2,930 724 3,409 1,731 3,722 4,672 2,649
      Increase Decrease In Inventories -240 3,161 4,587 386 -838 -409 -1,280
      Increase Decrease In Prepaid Deferred Expense And Other Assets -4,039 1,109 -456 504 -9 153 -95
      Increase Decrease In Accounts Payable And Accrued Liabilities -6,058 3,255 -6,518 3,882 -9,973 3,935 -1,059
      Increase Decrease In Customer Advances And Deposits -276 424 138 -1,436 5,065 -1,038 20,377
      Increase Decrease In Other Operating Liabilities 1,421 269 812 -296 -759 -344 -653
    Increase Decrease In Other Operating Capital Net 990 -1,676 -2,582 -2,224 -1,006 702 -336
    Paid In Kind Interest - - - - - - -
    Gain Loss On Disposition Of Assets - - 6,546 - - - -
    Reorganization Items 1,050 - - - - - -
  Net Cash Provided By Used In Operating Activities Continuing Operations 79,219 86,460 76,961 90,403 86,921 90,088 -
  Net Cash Provided By Used In Operating Activities Before Reorganization Items 81,612 86,460 76,961 - - - -
  Adjustments For Reorganization Items To Cash Provided By Used In Operating Activities 2,393 - - - - - -
Net Cash Provided By Used In Investing Activities
  Net Cash Provided By Used In Investing Activities - - - - -98,229 -97,841 -95,256
Net Cash Provided By Used In Investing Activities Continuing Operations
  Payments To Acquire Property Plant And Equipment 77,992 77,713 86,290 96,706 99,034 97,841 95,256
  Proceeds From Sale Of Property Plant And Equipment - - 13,118 - - - -
  Payments To Acquire Businesses Net Of Cash Acquired - 8,343 11,858 - - - -
  Decrease In Restricted Cash - - - - 400 - -
  Net Cash Provided By Used In Investing Activities Continuing Operations -77,992 -85,310 -85,030 -96,706 -97,829 -97,841 -
  Proceeds From Sale Maturity And Collections Of Investments - 746 - 463 805 - -
Net Cash Provided By Used In Financing Activities
  Net Cash Provided By Used In Financing Activities - - - - 1,335 -5,238 16,409
Net Cash Provided By Used In Financing Activities Continuing Operations
  Proceeds From Warrant Exercises - - - - 6,870 - -
  Repayments Of Long Term Capital Lease Obligations 582 582 542 3,179 4,217 3,341 3,961
  Repayments Of Long Term Debt - 306,750 303,083 3,000 3,000 3,000 305,263
  Proceeds From Installment Financing - - - 4,336 2,780 2,155 2,423
  Proceeds From Issuance Of Long Term Debt - 295,500 298,500 - - - 330,000
  Payments Of Loan Costs - 4,130 3,442 - 150 688 6,295
  Payments Related To Tax Withholding For Share Based Compensation 25 258 806 1,520 948 364 495
  Net Cash Provided By Used In Financing Activities Continuing Operations -811 -16,220 -9,373 -3,363 1,335 -5,238 -
  Proceeds From Issuance Of Common Stock 49 - - 4,336 - - -
  Payments Of Debt Restructuring Costs 253 - - - - - -
Net Cash Provided By Used In Continuing Operations 416 -15,070 -17,442 -9,666 -9,573 -12,991 -
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect - - - - -6,298 -12,991 19,863
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents - - - - - 21,146 41,009
Cash And Cash Equivalents At Carrying Value 82,063 66,993 49,551 39,885 30,312 15,821 40,759
Supplemental Cash Flow Information
  Interest Paid Net 25,323 21,966 18,094 14,667 16,178 13,706 14,666

Peers - Communications Services, Not Elsewhere Classified (4899)

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 420031106